╌>

Bioethicist: Ebola Treatment to West Is Troubling, Bad Science

  

Category:  News & Politics

Via:  screminmimi  •  12 years ago  •  9 comments

Bioethicist: Ebola Treatment to West Is Troubling, Bad Science

Spanish officials say a 75-year-old Roman Catholic priest who was infected with Ebola and flown back to Spain has received the same therapy as two American aid workers: an experimental treatment called ZMapp never before tested in humans.

ZMapp is not the answer to the Ebola epidemic ravaging West Africa. There is no chance of getting a significant amount of this drug made for many months. Deploying more health care workers, face guards, moon suits, gloves and antiseptic, along with restrictions on travel and burying the dead, is the only way to get the epidemic under control.

That said, it is very troubling that the only people to get the drug to date are two Americans and a Spaniard. The drug's maker, Mapp Biopharmaceutical, Inc., has said that "very little of the drug is currently available" and said Monday that it would release a statement soon.

The Americans appear to have gotten the drug because their missionary organization asked for it first. But since then, the Nigerian government and others in Africa have made requests without apparent success. More than 1,700 Africans have been infected with Ebola in the current outbreak, and the World Health Organization is convening a panel of medical ethicists this week to explore the use of experimental treatments.

The fact that a 75-year-old has been given the scarce drug is especially disturbing, not because he is 75 but because 75 year-olds do not have strong immune systems something very important in battling a virus like Ebola. Moreover 75-year-olds often have other medical problems that complicate the ability of scientists to figure out if the drug is safe and if it is really working.

In testing unapproved, highly risky drugs like Zmapp, it is crucial that recipients not be so sick that they may well die regardless of whether they get the drug or not. Indeed, the recipients ought not be very sick so that side-effects can be seen and efficacy determined. To do that, doctors need to be able to monitor experimental subjects for months to make sure the drug does not damage their livers or cause any other fatal side-effect. So not every person infected with Ebola makes for the best recipient younger, those more recently infected and those who can be closely monitored are among the "best" candidates.

Is money playing a role in the distribution of the drug? Yes, if for no reason other than the drug has been flown to the three recipients and they have been flown to top-flight hospitals in the hopes they will recover. Did the company itself demand payment for its drug? That is not known.

When all is said and done, we need more transparency about what the tiny company in San Diego is doing in rationing its small supply of drugs.

There are lots of people on the frontlines of the Ebola epidemic who are justifiably wondering what the moral basis is to-date for treating the three people who have gotten access to a last-ditch experimental treatment.

http://www.nbcnews.com/storyline/ebola-virus-outbreak/bioethicist-ebola-treatment-west-troubling-bad-science-n178026


Tags

jrDiscussion - desc
[]
 
screminmimi
Freshman Silent
link   seeder  screminmimi    12 years ago

Looks like the 75 year old white Spanish Catholic priest managed to get a dose of the we're-not-even-sure-it-really-works Ebola medicine too... but Africa is still being denied any of it.

Things may get nasty over this.

 
 
 
Swamijim sez
Freshman Silent
link   Swamijim sez    12 years ago

Watch for developments over the next week or so before you go off the deep end, mimi. Swamijim sez between the FDA backing down, WHO making 'special requests' & UK Ebola hotshots making waves, ZMappp and other 'experimental' procedures are going to be fast-tracked to Liberia et al before you an say "International Incident". NOT because the US FDA or the med-corp manufacturing the treatment have any 'humanitarian' considerations at all... The reality is that behind closed doors, every developed country on the planet is shitting bricks over the possibility of Ebola getting out of Africa & into some major urban population center. and will to anything to forestall that potential nightmare. You can bet that there's already discussion of how fast the US military bio-terrorist labs can churn out ZMapp, as well as folks working on how to get antibody-blood transfusion from Ebola survivors into production.

We're living in the era where yesterday's science-fiction 'impossibilities' are tomorrow's gruesome headlines. The MFICs ofthe 'developed' world don't give a rat's ass if most of the population of Africa dies off, but the possibility of Ebola making it to New York, London orShanghai has them pissing down their legs. The odds are good thatit's only a matter of time before Ebola (or something equally hideous) manages to 'emigrate' out of the boondocks to someplace 'important', so the current situation is the kind of 'omigod we don't have a contingency plan' scenario that will have people scrambling.

Welcome to the future...

 
 
 
palma
Freshman Silent
link   palma    12 years ago

the recipients ought not be very sick

depends on the phase of development. There are 4 phases in drg development during what is called clinical development"

Phase I - studies in healthy volunteers

Phase II - subjects with the target disease. It is dose-findng and the first studies to assess efficacy and safety in humans with the condition under study

Phase III - larger studies in subjects with the target disease to confirm the findings from Phase 2

Phase IV - post-marketing studies. Conducted after approval by Regulatory agencies

not every person infected with Ebola makes for the best recipient

they are the ones in whom efficacy and safety are confirmed

Did the company itself demand payment for its drug?

No

very little of the drug is currently available"

very possibly true. I don't know which phase of development this drug is but batches are produced according to the needs of clinical trials. Usually the initial trials are pretty small so not much drug is available. Even when a product is approved, in case of a large epidemic they have to go on overdrive t produce massive amounts of the drug which is not always possible

a last-ditch experimental treatment.

why last ditch? There's so much to drug development that people don't know about. For example, 1 out of 1,000 molecules that come from the lab will make it to market. And there's a lot of work associated with it, even when it fails. There's nothing more hurtful and frustrating as seeing a potential treatment, especially for a life-threatening or debilitating disease, fail

 
 
 
palma
Freshman Silent
link   palma    12 years ago

how fast the US military bio-terrorist labs can churn out ZMapp

I wish it was that easy

 
 
 
screminmimi
Freshman Silent
link   seeder  screminmimi    12 years ago

The American who died in Nigeria had made two trips to America after visiting his sick sister in Liberia.

The story about this guy changes every time I read something. He infected eight people in Nigeria, three have died, five are in quarantine in intensive care.

First time I read about him, the article said he had NOT visited his sister who had died from Ebola. Today I saw a video about his mother in Philadelphia who was crying about her dead son and dead daughter; seems he flew straight to his sister's side when he found out she was so sick and was right beside her when she died. Not only that, but the doctors did not know what she was dying of and no one took any precautions treating her, OR VISITING HER.

He made two trips to visit his wife and children AFTER his sister died. I think they live in Michigan. That would have been enough of a wake up call to get the ball rolling.

There is already something going on or that lab would not have had that drug ready for use, even at a test phase.

 
 
 
screminmimi
Freshman Silent
link   seeder  screminmimi    12 years ago

Thank you for the information, palma.

It makes me cringe a little to think of how desperate the African countries must be for even a little of the drug they are convinced is a miracle cure for this disease they see as a death sentence, and while it is tacky of the media to bring this tragedy down to the level of race, it's also difficult to understand why we would tell Africa "no" but would tell Spain "yes."

I suppose an argument could be made that one dose would not make a difference in Africa where so many are in need and the priest in Spain is only one man who might possibly be helped. But you still run into the weak argument by the US who said to Africa several days ago that "we aren't even sure the medicine had anything to do with the recovery" of the two doctors we brought back to Atlanta.

The public relations surrounding this drug is a boondoggle from the beginning.

 
 
 
Cerenkov
Professor Silent
link   Cerenkov    12 years ago
I predict more of it will be released to African nations. Then, side effects will be discovered. The US will be accused of attempted genocide while the drug company is sued out of business. No way to win.
 
 
 
Petey Coober
Freshman Silent
link   Petey Coober    12 years ago

Desperate are not interested in hearing the other possibilities in drug trials .

 
 
 
Cerenkov
Professor Silent
link   Cerenkov    12 years ago
Oh, I think providing the experimental drug is the right thing to do, given the mortality rate.
 
 

Who is online

Right Down the Center
devangelical
CB


94 visitors